Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $274M | $298M | $347M | $428M | $390M | $414M | $411M | $443M | $351M | $296M |
| Revenue growth | — | 8.9% | 16.2% | 23.6% | -9.1% | 6.2% | -0.8% | 7.8% | -20.6% | -15.7% |
| Operating income | -$51.9M | -$15.4M | -$151M | $120M | $143M | $232M | $250M | -$945M | $93.1M | $98.5M |
| Operating margin | -18.9% | -5.2% | -43.5% | 28.0% | 36.7% | 56.1% | 61.0% | -213.5% | 26.5% | 33.3% |
| Net income | -$81.7M | -$117M | -$282M | $21.5M | $106M | $528M | $175M | -$1.00B | $880K | $24.0M |
| Net margin | -29.8% | -39.2% | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% |
| EPS (diluted) | -$0.56 | -$0.78 | -$1.85 | $0.14 | $0.66 | $3.21 | $0.96 | -$6.45 | $0.01 | $0.15 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.9M | -$101M | -$70.9M | $10.7M | $169M | $262M | $274M | $183M | $104M | $127M |
| Capital expenditures | $4.21M | $2.80M | $351K | $7.19M | $1.84M | $265K | $136K | $273K | $142K | $34.0K |
| Free cash flow | -$30.1M | -$104M | -$71.2M | $3.54M | $167M | $262M | $274M | $183M | $103M | $127M |
| Share buybacks | — | — | — | — | — | $24.1M | $126M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $54.0M | $126M | $173M | $177M | $363M | $620M | $656M | $92.2M | $88.6M | $215M |
| Total assets | $710M | $606M | $332M | $403M | $559M | $1.13B | $1.10B | $471M | $351M | $397M |
| Long-term debt | — | — | — | — | $430M | $454M | $396M | — | — | — |
| Shareholders' equity | $66.7M | $9.85M | -$196M | -$93.3M | $62.6M | $606M | $652M | -$346M | -$301M | -$262M |
| Retained earnings | -$1.19B | -$1.31B | -$1.59B | -$1.57B | -$1.47B | -$938M | -$696M | -$1.70B | -$1.70B | -$1.67B |
| Shares (wtd avg diluted) | — | — | 153M | 156M | 161M | 164M | 186M | 155M | 160M | 163M |
Every figure is extracted from IRONWOOD PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.